Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
Clinical trial NCT02599064 · UNKNOWN
Trial details
- NCT number
- NCT02599064
- Sponsor
- RXi Pharmaceuticals, Corp.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-11-01
- Primary completion
- 2018-04-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.